JTJiao Tian

Jiao Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiao Tian has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Cheng Yang

    State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai-Baiyang Joint R&D Center for Basic and Translational Medicine of Organ Fibroproliferation, Nankai University

    1 shared publication
  • Henan Ma

    State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, College of Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin 300071, China

    1 shared publication
  • Honggang Zhou

    State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, China

    1 shared publication
  • Kaihua Wang

    State Key Laboratory of Medicinal Biology, College of Pharmacy, Nankai University, Tianjin 300353, China

    1 shared publication
  • Qingmin Wang

    Nankai University

    1 shared publication
  • Ting Xiao

    School of Pharmaceutical Sciences, Tiangong University, Tianjin 300387, China

    1 shared publication

Latest Publications

  • Open Access

    A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma

    by Xiyang Sun, Yiming He, Ting Xiao, Yuanmin Dong, Jiao Tian, Kaihua Wang, Henan Ma, Ziwen Wang, Honggang Zhou, Qingmin Wang, et al.

    Signal transducer and activator of transcription 3 (STAT3) drives multiple hallmarks of tumorigenesis, making it a validated therapeutic target for diverse cancers. The 1,4-naphthoquinones, such as plumbagin (PL), exhibit anticancer activity via inhibiting STAT3 phosphorylation and dimerization, but their severe cytotoxicity precludes clinical translation. Here, we screened 23 PL derivatives for STAT3 inhibitory activity and normal cell cytotoxicity, identifying III-1a as the optimal candidate with superior STAT3 inhibition and reduced toxicity compared to PL. Molecular docking and cellular thermal shift assay (CTESA) revealed that III-1a binds to the L244 residue within the coiled-coil domain (CCD) of STAT3. In vitro, III-1a dose-dependently suppressed JAK/STAT3 signaling in oral squamous cell carcinoma (OSCC), particularly STAT3 Ser727 phosphorylation. It inhibited STAT3-mediated epithelial—mesenchymal transition (EMT) and induced ferroptosis, thereby attenuating OSCC proliferation, invasion and migration. STAT3 knockdown abrogated its anti-tumor effects, and in vivo studies further confirmed its efficacy against OSCC growth. Collectively, this study identifies a novel PL-derived STAT3 inhibitor targeting STAT3 CCD to regulate EMT and ferroptosis, providing a promising therapeutic candidate for OSCC.